Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMMPACT: AXA1125 in Noncirrhotic NASH With Fibrosis
2021-000685-15Phase 2Terminated
- Sponsor
- Axcella
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AXA1125 in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (3 arms), sponsored by Axcella. Primary endpoint: Primary endpoints (Cohort A - adults). Started Jun 2021; status: terminated.
02
Drugs
AXA1125
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2021-000685-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000685-15.